

## **Astellas Voluntarily Adopts International Financial Reporting Standards (IFRS)**

Tokyo, February 28 2013 - [Astellas Pharma Inc.](#) (“Astellas”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) announced that it has resolved at a meeting of the Board of Directors held today that, as of the fiscal year 2013 (FY2013) ending March 31, 2014, it will voluntarily adopt the International Financial Reporting Standards (IFRS) for consolidated financial statements, in place of the Japanese Generally Accepted Accounting Principles (J-GAAP) previously followed.

Astellas is actively developing its business in Japan and in the global markets of the United States, Europe, Asia and elsewhere. Astellas also has a high level of overseas ownership, with more than 40% of Astellas shares being held by foreign shareholders. Given its global operations and shareholder composition, Astellas is voluntarily adopting IFRS as a means of enabling capital market participants to more readily compare the financial information on an international basis.

### Planned disclosure schedule for IFRS adoption

Date	Disclosure item	Reporting accounting standard
May 2013	Annual financial results announcement and Consolidated financial statements for FY2012 (ending March 31, 2013)	J-GAAP *1
June 2013	Annual securities report	J-GAAP
May 2014	Annual financial results announcement and Consolidated financial statements for FY2013 (ending March 31, 2014)	IFRS *2, *3
June 2014	Annual securities report	IFRS

\*1: Consolidated full-year business forecasts for FY2013 will be disclosed under J-GAAP.

\*2: Consolidated financial statements for FY2013 1Q through 3Q will be disclosed under J-GAAP.

\*3: As for consolidated financial statements for FY2013, differences between IFRS and J-GAAP will be disclosed separately.

###

For inquiries or additional information
Astellas Pharma Inc. Corporate Communications TEL: +81-3-3244-3201, FAX:+81-3-5201-7473 <a href="http://www.astellas.com/en">http://www.astellas.com/en</a>